NCT05373147 αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors Status UNKNOWN Phase EARLY_PHASE1
NCT05369286 A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors Status UNKNOWN Phase PHASE1
NCT05361954 Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors Status NOT_YET_RECRUITING Phase PHASE1
NCT05360368 HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors Status UNKNOWN Phase PHASE1
NCT05359718 The Psychological Impact of COVID-19 on Patients with Solid Malignancies: a Single-Institution Survey Study Status COMPLETED Phase N/A
NCT05359354 Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors Status RECRUITING Phase NA
NCT05357911 A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin Status COMPLETED Phase PHASE1
NCT05357820 A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK Status COMPLETED Phase PHASE1
NCT05357651 A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001) Status RECRUITING Phase PHASE1
NCT05346484 A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors Status TERMINATED Phase PHASE1
NCT05336279 Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition Status COMPLETED Phase PHASE1
NCT05323045 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 Status COMPLETED Phase PHASE1
NCT05322512 Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors Status NOT_YET_RECRUITING Phase NA
NCT05306509 Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology Status RECRUITING Phase NA
NCT05301101 High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis Status RECRUITING Phase NA
NCT05284968 RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid Tumors Status UNKNOWN Phase EARLY_PHASE1
NCT05284214 Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors Status WITHDRAWN Phase PHASE2